Navigation Links
One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
Date:3/19/2008

Although Two-Thirds of Surveyed Physicians Anticipate an Increase in the Number of Patients Treated for Low HDL Over the Next Two years, 19 Percent

of Surveyed MCOs Will Not Add Novel HDL Drugs to Their Formularies,

According to a New Report from Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately one-third of surveyed primary care physicians (PCPs) and cardiologists do not consider it necessary to treat low high- density lipoprotein (HDL) until patients' HDL levels drop below the recommended threshold established by the U.S. National Cholesterol Education Program's Adult Treatment Panel III guidelines.

The new Physician & Payer Forum primary market research report entitled Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies finds that most surveyed PCPs and cardiologists anticipate that the number of patients treated for low HDL will increase due to the launch of new HDL-raising therapies. These drugs, which offer improved tolerability and/or efficacy compared with currently available agents, include Merck's Cordaptive, Merck's MK-0524B and novel agents such as Merck's anacetrapib and Roche's dalcetrapib. However, 19 percent of surveyed managed care organizations' (MCOs) pharmacy directors said that they would not add any novel HDL drug to their private plan formularies. The report finds that MCOs have lower efficacy expectations than physicians do for new HDL-raising therapies and are more willing to trade off improvements in efficacy in return for treatments that offer better safety and tolerability.

"MCO pharmacy directors say that the most important key factors that would affect their willingness to include a novel HDL-raising therapy into their private plan formularies include outcomes data, low cost and efficacy in reducing low-density lipoprotein (LDL) cholesterol or high triglycerides in addition to raising HDL," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Drug companies are unlikely to get good formulary tier placement for novel HDL therapies on the basis of improved tolerability alone."

Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies is based on a U.S. survey of 73 U.S. cardiologists, 73 PCPs, and 21 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About High-Density Lipoprotein Cholesterol

Patients with low levels of HDL cholesterol are at elevated risk for cardiovascular disease, even if their levels of LDL cholesterol are well controlled. An estimated 50 percent of cardiovascular events occur in patients with low HDL, an under-treated disorder that afflicts nearly 30 million individuals in the United States. In 2007, agents that target low HDL achieved less than $800 million in sales, compared with close to $8 billion achieved by statins targeting high LDL.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
2. Acute lung injury patients one-third less likely to die in closed model ICUs
3. Over one-third of former American football players had sexual relations with men, study says
4. One-Third of Popular Songs Refer to Substance Abuse
5. New Gallup Survey Finds Half of Los Angeles Area Residents Have Taken in a Near-Homeless Person, One-Third Fear Homelessness Themselves
6. AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic
7. One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC
8. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
9. Kaiser Permanente Study Shows One-Third of Women Have Overactive Bladder, Incontinence or Other Pelvic Floor Disorders
10. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
11. Study finds primary care depression treatment often does not follow quality guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology: